New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTCYTK, RNA, NPSP, GEVA, CNAT, XOMA, RARE, NLNK, FOLD, ADXS, VRTX, PLX, ISISCanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
News For ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 15, 2014
09:04 EDTRAREUltragenyx initiates Phase 3 study of rhGUS, UX003
Subscribe for More Information
07:33 EDTADXSAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
07:10 EDTGEVASynageva announces active IND for SBC-103
Synageva BioPharma announced that the investigational new drug, or IND, application to the FDA to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB, also known as Sanfilippo B syndrome, is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015. The company recently completed a study assessing the integrity of the blood-brain barrier and other disease abnormalities in patients with MPS IIIB and plans to report data during the first quarter of 2015. The company is also conducting natural history studies in MPS IIIB. These include a retrospective natural history study of deceased MPS IIIB patients that began in July 2013 and a prospective, longitudinal natural history study in living MPS IIIB patients that began in September 2014.
December 12, 2014
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
09:16 EDTNLNKOn The Fly: Pre-market Movers
Subscribe for More Information
08:27 EDTNLNKNewLink Genetics falls after Ebola vaccine trial suspended
Shares of NewLink Genetics (NLNK) are falling in pre-market trading after a clinical trial of the Ebola vaccine being developed by the company and partner Merck (MRK) was temporarily suspended as a precautionary measure after four patients complained of joint pains in their hands and feet, the University of Geneva Hospital said. The trials are scheduled to resume next month in up to 15 volunteers after checks to make sure that the joint pain symptoms were benign and temporary, the hospital added. Shares of NewLink are down 6.5% to $34.50 in early morning trading following the news, while Merck shares are indicated to open fractionally higher.
07:32 EDTFOLDAmicus Therapeutics to submit EU MAA for migalastat HCl
Subscribe for More Information
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.
December 9, 2014
09:09 EDTXOMAXOMA raises $40M in a registered direct offering
XOMA (XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. Cowen and Company is acting as the sole placement agent.
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
07:35 EDTADXSAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information
December 4, 2014
15:00 EDTNLNKNewLink Genetics January and April volatility elevated
Subscribe for More Information
08:21 EDTXOMAXOMA March volatility elevated at 169
Subscribe for More Information
December 3, 2014
18:29 EDTISISOn The Fly: After Hours Movers
Subscribe for More Information
17:30 EDTRNABioMarin CEO says did deal for Prosensa while price still affordable
Subscribe for More Information
17:09 EDTISISIsis Pharmaceuticals reports results from Phase 2 study of ISIS-APOCIII
Isis Pharmaceuticals announced that data from a Phase 2 study of ISIS-APOCIII in patients with familial chylomicronemia syndrome were published in The New England Journal of Medicine. The paper, titled "Targeting ApoC-III in the Familial Chylomicronemia Syndrome," show that patients with FCS treated with ISIS-APOCIII achieved substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol particles. The three FCS patients in this open-label study had baseline triglyceride levels ranging from 1,406 mg/dL to 2,083 mg/dL and all three patients achieved triglyceride levels below 500 mg/dL during the study. FCS is a rare genetic disorder characterized by severe elevated levels of triglycerides. Current treatment options do not adequately reduce triglycerides and, as a result, patients with FCS have increased risk of recurrent and potentially fatal pancreatitis and other complications.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use